Jun 17, 2026 · 2h 51m · wtf
Two Pharma Giants Who'd Never Met | Mankind & Dr. Reddy's | WTF is Pharma? · Nikhil Kamath
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Host Nikhil Kamath brings together pharmaceutical titans Rajiv Juneja of Mankind Pharma and G.V. Prasad of Dr. Reddy's Laboratories to dissect the science, distribution economics, global geopolitics, and emerging entrepreneurial opportunities within the pharmaceutical industry.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nikhil holds 22.6% of the talking time here. How this is scored →
Nikhil as informed peer 4.2 Guest teaching 4.8 Guest disagreement 2.5 Nikhil pushing back 2.6
speaking balance: gold is Nikhil, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 2:05:47 Prasad defends industry ethics against Rajiv's marketing cynicism
Prasad forcefully interrupts and refutes Rajiv's claim that pharmaceutical companies conceal side effects, adamantly maintaining that top-tier pharma operates under strict ethical standards.
Hardest push from Nikhil ▶ 2:21:00 Nikhil persists on surrogate marketing angles for GLP-1sNikhil continually challenges the guests' dismissals by proposing proxy marketing schemes and ancillary business hacks for young entrepreneurs despite regulations.
Biggest teaching moment ▶ 1:50:35 Prasad breaks down recombinant DNA and living cell biologicsPrasad delivers a masterclass on how biologics differ fundamentally from chemical synthesis by cloning DNA into living cells and fermenting large molecules.
Nikhil holds their own ▶ 44:43 Nikhil cites his direct retail pharmacy backgroundNikhil establishes first-hand operational credibility by detailing his experience running a physical pharmacy and negotiating display fees at age 17.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Nikhil as informed peer | Guest teaching | Guest disagreement | Nikhil pushing back | Why |
|---|---|---|---|---|---|---|
| Ground Rules and Rajiv Juneja's Humble Beginnings | 2 | 3 | 1 | 1 | Nikhil sets the ground rules of framing the session as a masterclass for 25-year-old entrepreneurs. Rajiv Juneja shares his humble beginnings in Meerut, dropping out of college, working in a retail medical shop, and launching Mankind in 1995. | |
| Contrasting Business Models: FMCG Commando vs. R&D Scientist | 3 | 3 | 1 | 1 | Prasad contrasts Mankind's aggressive FMCG-style commando execution with Dr. Reddy's deep science roots. Both guests share their early career pivots and early setbacks during the 1980s. | |
| Foundational Strategic Advice for New Pharma Entrepreneurs | 3 | 5 | 1 | 2 | After admiring Nikhil's art collection, Prasad breaks down the primary segments of the Indian pharmaceutical industry, explaining why branded generics represent the largest revenue share. | |
| The Science of Bioequivalence, Excipients, and Approvals | 3 | 6 | 1 | 2 | Prasad delivers a clear scientific tutorial on bioequivalence, pharmacokinetics, and how generic formulations match the innovator's drug concentration release curve within a 20% margin. | |
| Drug Purity Standards, Shelf Life, and the US Perception Bias | 4 | 5 | 4 | 3 | Nikhil asks why American tablets feel more potent than Indian equivalents. Rajiv claims US regulatory impurity thresholds are stricter, but Prasad firmly contradicts him, insisting regulatory limits on impurities are identical globally. | |
| The Macro Economics of Indian Pharma: Margins, Scale, and Value | 5 | 4 | 1 | 2 | Nikhil probes the macro numbers of Indian pharma ($60B total split evenly between domestic and export), gross margins (60-70%), and EBITDA margins (22-25%), highlighting that India supplies 60% of global volume but captures barely 5% of value. | |
| Pharma Distribution Mechanics: Reps, Doctors, and Margins | 6 | 4 | 1 | 3 | Rajiv outlines the distribution economics from 100 MRP down to pharmacy margins (20%), wholesalers (10%), and C&F depots (2%). Nikhil shares his personal background running a pharmacy at age 17 to contextualize channel schemes. | |
| The Viability of E-Pharmacies, Supplements, and Branding | 4 | 4 | 2 | 3 | The guests evaluate the difficulty of building profitable e-pharmacies and explain why capital requirements make it prohibitive for newcomers, steering 25-year-olds toward differentiated supplements and clever brand naming. | |
| Hospital Economics, Valuation Multiples, and Star Doctors | 6 | 4 | 2 | 4 | Nikhil questions the private equity thesis driving Indian hospital chains to 80-90x EBITDA multiples. Prasad and Rajiv analyze bed addition mechanics, star doctor revenue dependence, and differential pricing models. | |
| Tariffs, Jan Aushadhi Stores, and Government Price Capping | 4 | 5 | 2 | 2 | The guests explain US tariff exemptions for generic medicines under essential commodity frameworks, the commercial viability issues faced by Jan Aushadhi franchise owners, and government price capping on essential medicines. | |
| China's Surge in Global Drug Innovation and Biotechnology | 5 | 6 | 3 | 3 | Prasad explains China's leap to number two globally in drug innovation through state-backed venture funds and talent repatriation. Nikhil draws parallels to Deng Xiaoping's meritocratic governance model while Rajiv and Prasad debate Indian intermediate reliance. | |
| Bureaucracy, Entrepreneurial Fear, and API Intermediates | 5 | 4 | 2 | 3 | The conversation explores state incentives for returning diaspora scientists and Nikhil emphasizes the need to eliminate regulatory red tape and entrepreneurial fear in India to foster high-stakes innovation. | |
| The Ayurveda Explosion: Evidence-Based vs Traditional Medicine | 5 | 4 | 6 | 3 | A stark philosophical divide emerges over the $30B Ayush sector: Prasad dismisses Ayurveda due to a lack of double-blind clinical evidence, while Rajiv ardently defends time-tested empirical usage and Mankind's commercial offerings. | |
| Ayush Regulation, Preventative Healthcare, and Longevity | 4 | 4 | 5 | 3 | Rajiv supports cross-practice and integration for Ayush doctors while Prasad insists that without scientific curriculum standardization and merit-based qualification, the healthcare system cannot safely scale. | |
| Sexual Wellness, IVF Treatments, and Demographic Shifts | 5 | 3 | 1 | 2 | Rajiv breaks down the rapid rise of quick-commerce sales for sexual wellness and pregnancy detection products driven by anonymity, while the table analyzes fertility trends and IVF market growth across urban India. | |
| Science Primer: APIs and Small Molecule Organic Synthesis | 3 | 7 | 4 | 3 | Prasad provides a chemistry tutorial on small-molecule active pharmaceutical ingredients (APIs), explaining synthesis from chemical intermediates. He disputes Rajiv's claim that Chinese intermediate dominance constitutes a catastrophic national security crisis. | |
| Science Primer: Biologics, Monoclonal Antibodies, and Peptides | 4 | 7 | 3 | 3 | Prasad educates Nikhil on biologics, explaining recombinant DNA insertion, living cell fermentation, and monoclonal antibodies. When Nikhil admits to taking stem cells and salmon sperm DNA, Prasad firmly advises against unproven therapies. | |
| The GLP-1 Weight Loss Boom and Pharmaceutical Marketing Ethics | 4 | 5 | 7 | 3 | Rajiv claims pharma marketing typically ignores side effects and that Mankind focuses on selling lifestyle ancillaries alongside GLP-1s. Prasad forcefully pushes back, stating top pharma companies are ethically bound to disclose risks and rejecting Rajiv's characterization. | |
| The Pipeline Shift to Large Molecules and Vaccine Impact | 4 | 6 | 2 | 2 | Prasad outlines the macro pivot from small-molecule chemistry to large-molecule biologics, peptides, and oligonucleotides, highlighting where India currently lags behind China's biologic infrastructure. | |
| GLP-1 Business Ideas: Lifestyle Ecosystems vs Compounding | 5 | 5 | 4 | 6 | Nikhil repeatedly pitches startup concepts around GLP-1 branding and surrogate marketing. Both guests firmly reject these ideas as illegal for prescription drugs, though Prasad describes how US compounding pharmacies exploited shortage loopholes. | |
| Innovators vs Generics: The Yin and Yang of Pharma | 4 | 6 | 1 | 2 | Prasad details the 'yin and yang' relationship between innovator pharmaceutical firms spending billions on high-risk discovery and generic manufacturers who challenge patents to expand public accessibility. | |
| CDMO Opportunities and the Future of Indian R&D | 4 | 5 | 1 | 2 | The guests discuss tailwinds for Indian CDMOs arising from the US Biosecure Act and China-plus-one diversification, using Anthem Biotech's journey as an inspirational case study for scientists. | |
| Niche Pharma Opportunities: AI, Expired Drug Logistics, and Shelf Life | 4 | 5 | 4 | 3 | Rajiv identifies reverse logistics and authenticated destruction of expired medicines as an unglamorous startup opportunity. When Rajiv suggests expired drugs at 95% potency could aid poor patients, Prasad strongly intervenes on toxicological safety. | |
| Founder Playbooks, Diagnostics, and the Decade Ahead | 4 | 4 | 1 | 2 | Rajiv shares his foundational playbook of dominating hyper-local territories before expanding, while Prasad outlines the future potential of microfluidic single-drop diagnostics and closing advice for young founders. |
Statements from this episode (59)
Juneja: Pharma sales reps for unbranded companies must become personal brands
“So when you work in that kind of a company, ah, if you will not become a brand yourself, ah, company will not run.”
Juneja: 1984 Meerut pharma venture started with ₹69,000 outperformed Glaxo locally
“One time that company start, which was started with 69,000 rupees in 84, became Merit's number one company. We had written Blaxos, Cibla, any company, everybody. Every company.”
Juneja: Mankind Pharma’s hypertension drug Telmikind generates ₹1,000 crore in revenue
“One product, which is quite a big one, is tell me kind. It's for hypertension. 1000 crore rupees.”
Juneja: Mankind Pharma’s Manforce condom brand generates ₹600 crore in revenue
“Second brand would be Manforce. That's quite a known name. Condoms. Around together, 600 crore rupees.”
Prasad: Indian pharma now requires extreme competitiveness compared to the 1980s
“When we started our business, you just had to make the product to make money. Now we have to be very good, excellent, highly competitive. The business has become very crowded, there are not many people here, and the whole thing is scaled.”
Prasad: Generic pharma makers conduct R&D before innovator patents expire
“Even before it runs out, you can do the R&D work. Keep it ready for the day the patent expires and then sell it.”
Prasad: Generic injectables avoid human trials by relying on analytical verification
“Injections are simpler in some ways, because you just have to establish analytically that they are the same solution that you are putting in the body. Sometimes they are not, then you have to do studies on humans.”
Prasad: Innovator drug production costs represent only 3% of the price
“See, the cost of production is not material during the patent time. Right. So they don't. Three percent, four percent.”
Prasad: Generic oral tablets must match innovator release curves within 20%
“You can develop the pill, So that it releases in the same way. Right. As the innovator's product does. Right. Within a margin of 20%. So if you, if it's x milligrams has dissolved in your body over the, if eight hours, it should be within 20% of that eight hou…”
Juneja: Indian pharmaceutical companies manufacture up to 50% of US medications
“That 40, 50% price that you buy over there are manufactured here. Indian companies.”
Prasad: Global drug impurity limits are identical, but enforcement varies drastically
“The standards are the same everywhere. How their enforced are different. I think the standard of Indian regulators limits on impurities, impurities are perfectly fine.”
Prasad: Consumers must rely on brand quality because supplements are poorly regulated
“See, supplements are not well regulated. Right. So you're better off taking from a good brand who has good internal quality systems than rely on a regulatory system to do this.”
Juneja: India’s top 50 pharma companies command 80% domestic market share
“Top 50 companies have a share of more than approximately 80%.
75, 80%.”
Juneja: Mankind Pharma intentionally caps EBITDA at 26% to fuel growth
“See, I mean, it depends upon, I mean, if you just look at mankind, our EBITDA is always in between 25, 26%.
Intentionally.
Because we just want to grow faster.
We spend more.
We can increase it.”
Prasad: US drug prices drop over 95% post-patent with five competitors
“So in the U.S., the innovator price, if it's a hundred, post-patent expiry, if there are more than five players, the price falls to north of, the discount falls north of 95%.
It can be sometimes one percent, two percent of the innovator's price.”
Juneja: Branded generics account for 95% of all drugs sold in India
“In India, first of all you're supposed to understand that, I mean 95% products are branded generic.”
Prasad: Dr. Reddy's Laboratories employs 10,000 pharmaceutical field sales representatives
“I think we have 10,000.”
Juneja: Mankind Pharma intentionally priced products 60% below leading competitor brands
“Keeping everything in mind, we intentionally kept our prices, 50%, 60%, 40%, more affordable than best of the companies.”
Prasad: E-pharmacies are highly capital intensive and Tata 1mg remains unprofitable
“Online business can happen, but then you require a huge amount of capital. It's not a twenty-five-year-old's job. Tata MG, One MG is still not profitable.”
Juneja: Gen Z supplement buyers prioritize attractive branding and flavors over price
“Cost is not the most important thing in this Gen Z crowd. I mean, for example, this youth, where if somebody is concerned about his health, he wants a flavor, he wants a good looking, ah, tablet, capsules. I mean, see point is not, ah, bringing the same thing …”
Juneja: Mankind Pharma will not acquire Bold Care due to Manforce ownership
“Are you interested in buying Bold Care? No. We have our own man force. We've got many opportunities of buying them in different kind of brands, but man force is man force.”
Juneja: Only 20% of Indian doctors are affiliated with hospital chains
“So I feel today approximately 15, 20% doctors would be attached with hospitals.”
Prasad: Scaling hospital chains is difficult because it is fundamentally real estate
“I think it's a very difficult game to scale because it's a real estate play at the end of the day.”
Prasad: Hospital bed revenue is driven almost entirely by star doctors
“If you take any chain, the hospital which delivers the maximum revenue per bed will be the one where the stars are.”
Prasad: US 100% tariffs on non-US innovative drugs threaten Indian CDMOs
“No, if you're selling it to the US, and it's an innovative drug, not a generic drug, and it's not manufactured in the US, it's manufactured in India, there is a likelihood of a hundred percent tariff. So this affects our CDMO industry, the contract development…”
Juneja: Low drug prices make government Jan Aushadhi pharmacy franchises commercially unviable
“Because if you sell something at a very cheap price, to run that Jan Ojdi, is a problem. You can look, if your daily sale is say, for example, 2000 rupees, what will you earn out of that? You need to have at least 50,001 lakh rupees sales daily. Then you earn …”
Prasad: China now produces 29% of all new cancer drugs globally
“29% of all new drugs are now, I think, in cancer are coming from China.”
Prasad: China originates 70% of novel antibody-drug conjugate biologics globally
“70% of the biologics, which are novel biologics ADCs are coming from there.”
Prasad: India profits more by converting cheap Chinese intermediates into finished APIs
“They're selling these cheap intermediates to us. We convert them into API. We make more money than them.”
Prasad: China saw approximately $50 billion in pharmaceutical deal making last year
“Fifty billion or so last year's deal making in from China. And all the global trials are coming from China now.”
Kamath: Excessive regulatory fear and red tape stifle Indian entrepreneurship
“India has too much fear in entrepreneurship where everybody is worried about this agency, that tax, this red tape, that has to structurally go away.”
Prasad: In-licensed Chinese molecule hit ₹100 crore in its launch year
“Not a very huge money. But you know, it's already a hundred crore brand in this year. Launch, year of launch. We could never achieve such results.”
Prasad: Dr. Reddy's clinical trials found no significant medical efficacy in turmeric
“We've done trials with turmeric, we didn't see significant.”
Juneja: Weak regulation leads to heavy metals like lead in Ayurvedic drugs
“The purity is an issue, actually. And a lot of time when regulatory is not very, very strong there are complaints of, I'll say, adding certain other things in that. For example, in this in some of the drugs, lead has been found.”
Juneja: Ayurvedic doctors lose patients if they prescribe only slow-acting Ayurvedic remedies
“If a patient is coming to him, and if he prescribes only Ayurveda product, the patient will not come back to him. Because patient needs what? Instant relief. Faster relief.”
Juneja: Prevention and immunity are the biggest commercial opportunities in Ayurveda
“Biggest in Ayurveda would be prevention side or immunity side.”
Juneja: Online sales of condoms in India are growing at 60% annually
“And if you just look at this right now, there is approximately, 50, 60% growth of condom sales online.”
Kamath: India's fertility rate has dropped below replacement level in most states
“Soon, if we don't have kids, I think that fertility ratio has dropped below 2.1, which is the replenishment ratio. In most states, outside of Bihar and UP or something, people are not having two kids.”
Juneja: Halting Chinese intermediate supplies would spark an Indian antibiotic crisis
“A lot of antibiotics are there. In the absence of Chinese supply, we can come into a crisis.”
Prasad: Dr. Reddy's found Chinese suppliers more reliable than Indian peers during COVID
“In COVID time, I'm telling you this, in COVID time, we had more reliable supplies from China than from Indian companies.”
Prasad: Indian API manufacturers primarily compete against each other, not China
“India is a big exporter of APIs. In fact, the competition is severe among Indian companies. It's not the Chinese which are competing with us.”
Prasad: Elective commercial stem cell therapies lack clinical evidence and FDA approval
“They are not FDA approved... They're all, you know, lack of evidence. They just, you know, Do something largely originating in Korea, China... It's business.”
Kamath: I receive salmon sperm DNA injections in my knees and elbows
“In my knees and elbows, I get salmon sperm DNA.”
Prasad: GLP-1 weight loss drugs cause significant muscle loss alongside fat reduction
“It's not just fat that you lose. You lose muscle.”
Juneja: Mankind will use semaglutide as a frontend to cross-sell lifestyle supplements
“So what our philosophy is, along with this, our focus would be on supplements. I mean, this would be front end, but actually, we will be selling the complete lifestyle. Protein, supplements, vitamins, other requirements. The complete, I mean, chain, the ecosys…”
Prasad: Global drug development pipeline is shifting from small molecules to biologics
“Pipeline used to be largely small molecules. It's now shifting to large molecules in biologics and peptides, and also another class of compounds called oligonucleotides.”
Prasad: China is significantly ahead of India in developing biologic drugs
“Indian abilities and scientific and manufacturing abilities and biologics are lagging. China is way ahead of us in biologic drugs. I wouldn't say that in chemistry, but I'll say that in biologics.”
Prasad: Novel biologics require lower capital intensity to develop than small molecules
“You can also generate novel biologics at a relatively lower intensity of cost than small molecules. It's easier to develop.”
Juneja: GLP-1 adoption will drive increased sales of protein and nutritional supplements
“What we basically imagine, going forward, the sales of protein products, different kind of proteins, supplements, protein supplements, vitamins, minerals, other enzymes, cocaine, all sort of things, they will further increase.”
Prasad: US entrepreneur sold $1B in compounded GLP-1 drugs at 90% margins
“I know a guy who was sold more than a billion dollars worth of product at 80, 90% gross margin.”
Juneja: Heavy pharma R&D requires a global market presence to be viable
“If you're basically spending money on R&D, you're supposed to have global presence. Then only it will make some kind of a sense. Only from India, not possible.”
Prasad: Generics and drug innovation are fundamentally different business models
“Innovation and generics They are not a continuum. People like to say, we're moving up the value chain, we're going to innovation. It's a very different business.”
Prasad: China produces semaglutide far more efficiently via biologics than India can
“The Chinese are much better at biological processors, and the GLP-I they make, the semaglutide they make is from a biologic route. So they're able to scale it much, much better than Indians. Indian companies are largely in synthesis, which is an inefficient wa…”
Juneja: Mankind Pharma spends 2.75% of revenue on R&D, planning annual increases
“See, a company like us, we spend 2.75% on R&D. And what we've decided now, every year, we're supposed to increase it by 5.5%.”
Prasad: US Biosecure Act drives significant growth for Indian pharma manufacturing organizations
“For, you know, for their country's supply chain security, they passed a biosecure act, which encouraged companies to move out of China. Right. So there's a whole thing called China plus one strategy. Yeah. That's an opportunity for Indian companies. Indian com…”
Prasad: Pharma companies lack capabilities and struggle to attract top AI talent
“So the AI part is a big deal for us and we are not equipped to do it. Whether it's in our Salesforce management, targeting doctors, all of that can be driven much more efficiently. Through agents and things like that. Our processes, R&D processes can improve. …”